Navigation Links
Omeros Reports Additional Positive Results from OMS824 Program
Date:9/12/2013

r/>Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery® platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has six clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the pharmaceutical industry. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. These statements include, but are not limited to, Omeros' expectations regarding the potential competitive advantages of OMS824, including its therapeutic benefits; that it will advance OMS824 into Phase 2 clinical programs for Huntington's disease and schizophrenia before year end; regarding the potential qualities of OMS824; regarding demonstration of target engagement in the PET trial; and that it may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the pharmaceutical industry. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could di
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
2. Omeros to Present at the Stifel Healthcare Conference 2013
3. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
4. Omeros Corporation Reports Second Quarter 2013 Financial Results
5. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
6. Omeros Submits New Drug Application to U.S. FDA for OMS302
7. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
8. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
9. Omeros Corporation Reports First Quarter 2013 Financial Results
10. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
11. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 The ... are evolving across industry sectors to better identify ... better ways to engage with and understand consumers, ... themselves and make critical purchasing decisions. ... Best Practices, LLC, one area where organizations can ...
(Date:7/11/2014)... 2014 Research and Markets has ... Medical X-ray Film Industry Report 2014" report to ... Global And Chinese Medical X-Ray Film Industry ... the current state of the Global medical X-ray film ... The report provides a basic overview of the industry ...
(Date:7/11/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... is a hollow needle commonly used with a syringe ... extract fluids from it. A hypodermic needle is used ... that cannot be ingested. Hypodermic needles are broadly classified ...
Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Global and Chinese Medical X-ray Film Industry Report 2014 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... Pa., Aug. 31, 2011 Unilife Corporation ("Unilife" ... today announced that its Chief Operating Officer, Dr. Ramin Mojdeh, ... common stock. This investment closely follows Dr. Mojdeh,s initial open ... March 2011, six weeks after he joined the Company. ...
... 31, 2011 Accuray Incorporated ... radiation oncology company, announced today the launch of ... organization for CyberKnife® Robotic Radiosurgery System and TomoTherapy® Radiation ... worldwide clinical and technical collaboration. AERO,s ...
Cached Medicine Technology:Unilife COO to Again Purchase More Than $250,000 in Company Shares 2Unilife COO to Again Purchase More Than $250,000 in Company Shares 3Accuray Launches New Organization for CyberKnife® and TomoTherapy® System Users 2Accuray Launches New Organization for CyberKnife® and TomoTherapy® System Users 3Accuray Launches New Organization for CyberKnife® and TomoTherapy® System Users 4
(Date:7/11/2014)... Biostimulants are widely applied in turf and ornamentals. They ... help turf and ornamentals in absorption of water, nutrient ... flowers appear healthy and strong as a result of ... last few years. The most dominating region in biostimulants ... 40% share in 2013, and is estimated to grow ...
(Date:7/11/2014)... PROVIDENCE, R.I. -- Researchers from The Miriam ... under age 65 have significantly higher rates of ... with mobility impairments were less likely to attempt ... quit-smoking treatments may not be sufficient for this ... online in advance of print in the ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... five years to 2014 on the heels of fresh ... prompted farmers to dedicate a larger share of their ... More specifically, the regulations required the mixing of 5.0% ... biofuel production in the United States created a key ...
(Date:7/11/2014)... Prostate cancer patients are more likely to be diagnosed ... sooner if they also have depression, a new study ... American men who were diagnosed with localized prostate cancer ... Nearly 1,900 of the patients had been diagnosed with ... was discovered. "Men with intermediate- or high-risk prostate ...
(Date:7/11/2014)... 11, 2014 Riverside Health System became the ... in Virginia in late 2012 and now, in partnership with ... residents throughout the Williamsburg and Newport News region. , Also ... and benefits to independent older adults who wish to remain ... safety net of continuing care services as well as control ...
Breaking Medicine News(10 mins):Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Miriam Hospital study examines smoking prevalence 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Depression May Make It Harder to Beat Prostate Cancer 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
... Lube Leader Reaches Halfway Point in Campaign to Support American ... Heart Association,s Go Red For Women(TM) Movement, HOUSTON, Feb. ... to its goal of raising $1 million for the,American Heart ... Heart Month are almost in the rear-view mirror, Jiffy,Lube wants ...
... according to a study of more than 77,000 vitamin ... risk of developing it. , Our study of supplemental ... show any evidence for a decreased risk of lung ... of the University of Washington, in Seattle. Indeed, increasing ...
... and a decision algorithm, rather than standard hospital protocols, ... patients with severe sepsis or septic shock can reduce ... costs all without adverse effects on patients, according to ... possible to customize antibiotic treatment duration in patients with ...
... UT Southwestern Medical Center have determined that the level, or ... children with sickle cell anemia who are at an increased ... have also found that a published method used to predict ... , Stroke is a serious but increasingly preventable complication of ...
... affected by ... rare diseases, NEW YORK, Feb. ... Day will be launched on Friday 29,February...because it,s a rare day that ... Shire plc at:, http://media.medialink.com/WebNR.aspx?story=34701 ), Collectively, rare diseases aren,t ...
... to Reliance on Spill-Proof,Cups, GLENDALE, Calif., Feb. 28 ... Dental Hygienists, Association,(CDHA) today urged parents and caregivers to ... "We all know that sippy cups are a godsend ... "But they need to be used wisely and,properly in ...
Cached Medicine News:Health News:Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 2Health News:Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 3Health News:Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 4Health News:Certain vitamin supplements may increase lung cancer risk, especially in smokers 2Health News:Customized treatments for sepsis lower treatment time and reduce length of ICU stays 2Health News:UT Southwestern researchers investigate predictors for sickle-cell-anemia complications 2Health News:VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda 2Health News:VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda 3Health News:California Dental Hygienists Offer Tips for Safe Sippy Cup Use 2
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... The Carpal Solution offers relief from CTS ... is different from other over-the-counter CTS treatments. ... Worn during sleep, the Carpal Solution gently ... Carpal Tunnel and eliminates hand pain, numbness ...
... Linearity is a whole blood formulation ... range of the most popular glucose ... of using a control matrix that ... is packaged in ready-to-use dropper vials ...
... ESR-10 Manual Rack is a manual ... the erythrocyte sedimentation rate (ESR) of ... 1.2ml Streck ESR-Vacuum Tubes. The rack ... simultaneously. The ESR-10 Manual Rack exhibits ...
Medicine Products: